AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33480241 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM (6.0 g/kg)
Number of subjects: 72
Study 32046754 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation (TTNS)
Number of subjects: 99
Study 32046754 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasacral Transcutaneous Electrical Stimulation (PTES)
Number of subjects: 99
Study 32046754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 34668569 — intervention group
Group type: EXPERIMENTAL
Intervention: Springboard Beyond Cancer eHealth self-management program
Number of subjects: 176
Study 34668569 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high engagement in the text and/or web intervention (n = 30)
Number of subjects: 176
Study 34668569 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 88)
Number of subjects: 176
Study 33892682 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENTURE programme targeting impulsivity, sensation-seeking, negative thoughts, and anxiety.
Number of subjects: 700
Study 33892682 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENTURE programme
Number of subjects: 700
Study 33892682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 700
Study 32174130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Attenuation Plaque Burden
Number of subjects: 1769
Study 32174130 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Calcium Score
Number of subjects: 1769
Study 32174130 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Coronary Artery Disease
Number of subjects: 1769
Study 32174130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Attenuation Plaque Burden >4%
Number of subjects: 1769
Study 35623754 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempters overall
Number of subjects: 1039
Study 35623754 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempters within 5 years
Number of subjects: 1039
Study 35623754 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempters after 5 years
Number of subjects: 1039
Study 35623754 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent method attempters (VA)
Number of subjects: 1039
Study 35623754 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated suicide attempters (RA) and high intent attempters (HS)
Number of subjects: 1039
Study 34951682 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) at 60–70% HRpeak for 30 min/session (n = 34, 150 min/week)
Number of subjects: 99
Study 34951682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 4 × 4 min bouts at 85–95% HRpeak (n = 34, 38 min/session, 114 min/week)
Number of subjects: 99
Study 34951682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 1 × 4 min bout at 85–95% HRpeak (n = 31, 17 min/session, 51 min/week)
Number of subjects: 99
Study 32981268 — intervention group
Group type: EXPERIMENTAL
Intervention: Urtica Dioica root extract (UDE) 450 mg day‐1 for 12 weeks
Number of subjects: 60
Study 32981268 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 34396685 — intervention group
Group type: EXPERIMENTAL
Intervention: SKH app intervention (experimental group I)
Number of subjects: 116
Study 34396685 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based intervention (experimental group II)
Number of subjects: 116
Study 34396685 — intervention group
Group type: COMPARATOR
Intervention: Usual intervention (control group)
Number of subjects: 116
Study 32414368 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational eHealth tool
Number of subjects: 286
Study 32414368 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 286
Study 35565243 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine (NAL) 0.2 mg, once daily
Number of subjects: 120
Study 35565243 — intervention group
Group type: COMPARATOR
Intervention: Magnesium Oxide (MgO) 500 mg, thrice daily
Number of subjects: 120
Study 34936275 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical moxibustion (7 moxa cones, 2 times a week for 8 weeks)
Number of subjects: 60
Study 34936275 — intervention group
Group type: COMPARATOR
Intervention: TCM health guidance (diet and exercise)
Number of subjects: 60
Study 34936275 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical moxibustion
Number of subjects: 60
Study 34936275 — intervention group
Group type: COMPARATOR
Intervention: TCM health guidance
Number of subjects: 60
Study 36454569 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine infusion (0.3 mg/kg/h)
Number of subjects: 183
Study 36454569 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 183
Study 34857076 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 40
Study 34857076 — intervention group
Group type: COMPARATOR
Intervention: Control (no binder)
Number of subjects: 40
Study 32461015 — intervention group
Group type: EXPERIMENTAL
Intervention: TaTME
Number of subjects: 64
Study 32461015 — intervention group
Group type: COMPARATOR
Intervention: LaTME
Number of subjects: 64
Study 32461015 — intervention group
Group type: EXPERIMENTAL
Intervention: TaTME and LaTME
Number of subjects: 64
Study 32026173 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-mediated response to joint attention intervention
Number of subjects: 20
Study 32026173 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 34562067 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 200-600 mg of RO7049389
Number of subjects: 52
Study 34562067 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of 200-400 mg of RO7049389
Number of subjects: 52
Study 34562067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single ascending dose)
Number of subjects: 52
Study 34562067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple ascending doses)
Number of subjects: 52
Study 33484934 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg daily subcutaneous injection)
Number of subjects: 125
Study 33484934 — intervention group
Group type: COMPARATOR
Intervention: Control (routine high risk pregnancy prenatal care)
Number of subjects: 125
Study 33484934 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 125
Study 33484934 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study 33484934 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin and Control
Number of subjects: 125
Study 32356084 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 1: Research suggesting SO has biogenetic origins
Number of subjects: 201
Study 32356084 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2: Research suggesting SO is socially constructed
Number of subjects: 201
Study 32356084 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3: Research suggesting SO is biogenetic and socially constructed
Number of subjects: 201
Study 32356084 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 201
Study 34718173 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video decision support tool (5-minute video)
Number of subjects: 59
Study 34718173 — intervention group
Group type: COMPARATOR
Intervention: Verbal narrative of goals of care
Number of subjects: 59
Study 34127299 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based HPV vaccination program
Number of subjects: 22
Study 33371157 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of HT7 acupoint (30 times, 2 times/day, 5 times/week for 20 days)
Number of subjects: 72
Study 33371157 — intervention group
Group type: COMPARATOR
Intervention: Behavioral cognitive therapy technology (sleep hygiene and cognitive therapy)
Number of subjects: 72
Study 33371157 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 72
Study 32842825 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 20 µg
Number of subjects: 24
Study 32842825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32341356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol) 400 IU
Number of subjects: 187
Study 36196515 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using a 940 nm diode laser before dental injection
Number of subjects: 30
Study 36196515 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser) quadrant
Number of subjects: 30
Study 33629647 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-week exercise intervention
Number of subjects: 26
Study 34957988 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary rehabilitation
Number of subjects: 96
Study 34957988 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatment
Number of subjects: 96
Study 34652243 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT-LOUD
Number of subjects: 44
Study 34652243 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study 35652771 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator Interval (RI) approach
Number of subjects: 90
Study 35652771 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Capsule (PC) approach
Number of subjects: 90
Study 34140425 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-focused care
Number of subjects: 794
Study 34140425 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 794
Study 32231293 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC14 (fluorouracil, epirubicin and cyclophosphamide administered every 2 weeks)
Number of subjects: 1214
Study 32231293 — intervention group
Group type: COMPARATOR
Intervention: FEC21 (fluorouracil, epirubicin and cyclophosphamide administered every 3 weeks)
Number of subjects: 1214
Study 32231293 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC14
Number of subjects: 1214
Study 32231293 — intervention group
Group type: COMPARATOR
Intervention: FEC21
Number of subjects: 1214
Study 32231293 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC14 (in hormone receptor-negative tumours)
Number of subjects: 1214
Study 32231293 — intervention group
Group type: COMPARATOR
Intervention: FEC21 (in hormone receptor-negative tumours)
Number of subjects: 1214
Study 34111699 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation training (cognitive or behavioral approach)
Number of subjects: 108
Study 34111699 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study 32183798 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning training programme
Number of subjects: 17
Study 34768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage and EPI‐NO® device group
Number of subjects: 90
Study 34768453 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐massage group
Number of subjects: 90
Study 34768453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 32312333 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder supplementation (400 mg per tablet, 4 tablets daily)
Number of subjects: 90
Study 32312333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg starch per tablet, 4 tablets daily)
Number of subjects: 90
Study 35162482 — intervention group
Group type: EXPERIMENTAL
Intervention: Home midwifery assistance for one month after birth
Number of subjects: 51
Study 35162482 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 51
Study 34922726 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus Codeine 30 mg (group APAP/COD)
Number of subjects: 120
Study 34922726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg (group IBU)
Number of subjects: 120
Study 34922726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group PLA)
Number of subjects: 120
Study 35781789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-rapid lispro (URLi)
Number of subjects: 673
Study 35781789 — intervention group
Group type: COMPARATOR
Intervention: lispro (Humalog)
Number of subjects: 673
Study 32372432 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% EF
Number of subjects: 72
Study 32372432 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% EF
Number of subjects: 72
Study 32372432 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% EF
Number of subjects: 72
Study 32372432 — intervention group
Group type: COMPARATOR
Intervention: Control (0% EF)
Number of subjects: 72
Study 35562226 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. bolus remimazolam (0.02–0.27 mg kg−1)
Number of subjects: 120
Study 34852952 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymepearls (TP)
Number of subjects: 18
Study 34852952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 35126629 — intervention group
Group type: EXPERIMENTAL
Intervention: EM algorithm (algorithm group)
Number of subjects: 120
Study 35126629 — intervention group
Group type: COMPARATOR
Intervention: RAMP algorithm
Number of subjects: 120
Study 35126629 — intervention group
Group type: COMPARATOR
Intervention: Mean filter
Number of subjects: 120
Study 35126629 — intervention group
Group type: COMPARATOR
Intervention: PWLS algorithm
Number of subjects: 120
Study 35126629 — intervention group
Group type: COMPARATOR
Intervention: MS-PWLS algorithm
Number of subjects: 120
Study 35126629 — intervention group
Group type: EXPERIMENTAL
Intervention: EM algorithm
Number of subjects: 120
Study 35126629 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD
Number of subjects: 120
Study 34109365 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified posterior dental splint
Number of subjects: 89
Study 34109365 — intervention group
Group type: COMPARATOR
Intervention: Stabilization splint
Number of subjects: 89
Study 36091061 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal depression
Number of subjects: 30
Study 36091061 — intervention group
Group type: COMPARATOR
Intervention: Peritraumatic distress
Number of subjects: 30
Study 36091061 — intervention group
Group type: COMPARATOR
Intervention: Perceived stress
Number of subjects: 30
Study 33753893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 52
Study 33753893 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 52
Study 32981298 — intervention group
Group type: COMPARATOR
Intervention: Low glucocorticoid users (0< DDDs ≤45)
Number of subjects: 1896159
Study 32981298 — intervention group
Group type: COMPARATOR
Intervention: Intermediate glucocorticoid users (45< DDDs ≤90)
Number of subjects: 1896159
Study 32981298 — intervention group
Group type: COMPARATOR
Intervention: High glucocorticoid users (90< DDDs)
Number of subjects: 1896159
Study 34495079 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 6 months
Number of subjects: 100
Study 34495079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal strips) for 6 months
Number of subjects: 100
Study 34495079 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 100
Study 34495079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal strips)
Number of subjects: 100
Study 32126267 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (20 mg/m2) with postoperative radiation therapy (total dose 60-66 Gy)
Number of subjects: 91
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 135
Study 36096354 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 135
Study 32139240 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in FRIEND%PRED (age-predicted VO2peak)
Number of subjects: 1283
Study 32139240 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 1 unit % increase in FRIEND%PRED
Number of subjects: 1283
Study 35926726 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent live human-bovine reassortant rotavirus vaccine (HRV)
Number of subjects: 6400
Study 35926726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6400
Study 32031889 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 135 mg/week
Number of subjects: 151
Study 32031889 — intervention group
Group type: COMPARATOR
Intervention: Control (standard taxane- and anthracycline-based neoadjuvant therapy)
Number of subjects: 151
Study 36193841 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline insulin level
Number of subjects: 214
Study 32255279 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen mixed serum potassium candidate reference materials
Number of subjects: 0
Study 34634445 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Body‐Mind‐Spirit (IBMS)
Number of subjects: 281
Study 34634445 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 281
Study 34634445 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 281
Study 33058798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol 2 g every 8 hours for 7–14 days
Number of subjects: 300
Study 33058798 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 2 g every 8 hours for 7–14 days
Number of subjects: 300
Study 33058798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 300
Study 33058798 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 300
Study 32726308 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Clinical Decision Support System (CDSS)
Number of subjects: 31
Study 32726308 — intervention group
Group type: COMPARATOR
Intervention: Standard Consultations (SDR)
Number of subjects: 31
Study 35340578 — intervention group
Group type: EXPERIMENTAL
Intervention: DSN-led pathway
Number of subjects: 162
Study 35340578 — intervention group
Group type: COMPARATOR
Intervention: GP routine follow-up
Number of subjects: 162
Study 35340578 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 162
Study 33794804 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT-HIP intervention (multicomponent cognitive behavioral intervention)
Number of subjects: 39
Study 33794804 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 39
Study 35999682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive system
Number of subjects: 47
Study 35999682 — intervention group
Group type: COMPARATOR
Intervention: Conventional acid-etch
Number of subjects: 47
Study 34376180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) TXA
Number of subjects: 240
Study 34376180 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA in a PAMC injection for topical administration
Number of subjects: 240
Study 34376180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both intravenous and topical administration of TXA
Number of subjects: 240
Study 34376180 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 240
Study 34111690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosed exercise
Number of subjects: 302
Study 34111690 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention
Number of subjects: 302
Study 35135310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, doxycycline, zinc, vitamins D and C
Number of subjects: 24
Study 33794789 — intervention group
Group type: EXPERIMENTAL
Intervention: DemStepCare intervention (complex intervention with GP support by a multi-professional team)
Number of subjects: 800
Study 33794789 — intervention group
Group type: COMPARATOR
Intervention: Usual care (slightly expanded)
Number of subjects: 800
Study 33794789 — intervention group
Group type: COMPARATOR
Intervention: Aggregated routine data from German health insurance companies (second control group)
Number of subjects: 800
Study 32092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 7.5 mg
Number of subjects: 250
Study 32092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 250
Study 32092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 250
Study 32092309 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg
Number of subjects: 250
Study 32092309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 33201120 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 246
Study 33646842 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intermittent bolus of hypertonic saline
Number of subjects: 0
Study 33646842 — intervention group
Group type: COMPARATOR
Intervention: Slow continuous infusion of hypertonic saline
Number of subjects: 0
Study 36078774 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (16 weeks of combined training including walking/running at 63% of V˙O2max, three times per week, and strength training, consisting of one set of fifteen repetitions at moderate intensity, twice per week)
Number of subjects: 52
Study 36078774 — intervention group
Group type: COMPARATOR
Intervention: Control (remained physically inactive)
Number of subjects: 52
Study 33347829 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (carboplatin and pemetrexed)
Number of subjects: 419
Study 33347829 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 419
Study 33347829 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 419
Study 32957403 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-developed pelvic floor repair system
Number of subjects: 132
Study 32957403 — intervention group
Group type: COMPARATOR
Intervention: Avaulta repair system
Number of subjects: 132
Study 36123052 — intervention group
Group type: EXPERIMENTAL
Intervention: Afya conditional cash transfer (CCT) intervention
Number of subjects: 48
Study 36123052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 34736394 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized telephone-based care support (ITBCS) program for 3 months followed by 6 months of follow-up consultations.
Number of subjects: 168
Study 34736394 — intervention group
Group type: COMPARATOR
Intervention: Usual care services available for caregivers.
Number of subjects: 168